Originally published by our sister publication Gastroenterology & Endoscopy News
By GEN Staff
The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative colitis.
Joining other monoclonal antibodies for the treatment of UC, guselkumab has a unique mechanism of action in that it targets interleukin-23 and also binds to the CD64 receptor on cells that produce IL-23. Guselkumab was previously approved for use in patients with active psoriatic